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Recent evidence indicates that bone marrow-derived mesenchymal stem cells (BM-MSCs) possess immu-
nosuppressive properties both in vitro and in vivo. We have previously demonstrated that transplantation of 
human MSCs can significantly improve the autoimmune conditions in MRL/lpr mice. The current study aimed 
to determine the mechanisms by which murine BM-MSC transplantation (MSCT) ameliorates nephritis in 
MRL/lpr mice. In this study, we found that MSCT can significantly prolong the survival of MRL/lpr mice. 
Eight weeks after transplantation, MSCT-treated mice showed significantly smaller spleens than control ani-
mals, with fewer marginal zones (MZs), T1, T2, activated B-cells, and plasma cells. Moreover, serum levels of 
B-cell activating factor (BAFF) and IL-10 in MSCT-treated mice decreased significantly compared to those in 
the control group, while levels of serum TGF-b were increased. Notably, decreased BAFF expression in both 
spleen and kidney was accompanied by decreased production of anti-dsDNA autoantibodies and proteinuria in 
MSCT-treated mice. Since BAFF is mainly expressed by T-cells and dendritic cells, we incubated BM-MSCs 
and DCs together and found that the production of BAFF by DCs was suppressed by MSCs. Thus, our find-
ings suggest that MSCT may suppress the excessive activation of B-cells via inhibition of BAFF production 
in MRL/lpr mice.
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INTRODUCTION
Systemic lupus erythematosus (SLE) is a multisystem 
autoimmune disorder resulting from generation of auto-
reactive antibodies to nuclear antigens by B lymphocytes, 
which modulates the T-cell repertoire through cytokine 
production and antigen presentation, leading to distant 
organ damage (13,33). In addition, B-cells produce sol-
uble mediators involved in the organization of lymphoid 
tissues and in the initiation and perpetuation of inflamma-
tory processes (4,23). So, B-cell hyperreactivity may play 
an important role in SLE pathogenesis. Some researchers 
have hypothesized that B-cell depletion might represent 
an effective treatment for SLE (25).
B-cell activating factor (BAFF) is a tumor necrosis factor 
(TNF) family cytokine that is essential for B-cell survival 
and maturation (27). It binds to three receptors, namely, 
transmembrane activator and calcium modulator ligand 
interactor (TACI), B-cell maturation antigen (BCMA), 
and BAFF receptor (BAFF-R) (5,36). BAFF-transgenic 
(Tg) mice develop an autoimmune disease with hallmarks 
resembling human SLE, including autoantibodies against 
double-strand DNA (dsDNA), circulating immune com-
plexes, and severe membranoproliferative glomerulone-
phritis (28). Elevated serum levels of BAFF were found 
in autoimmune diseases, including SLE and rheumatoid 
arthritis (28). Blockade of BAFF using soluble fusion pro-
teins of BAFF receptors prevented autoimmunity in ani-
mal models of the disease (15,34). Belimumab (Benlysta, 
Human Genome Sciences, Rockville, MD, USA) is a 
human G1-l monoclonal antibody that binds to soluble 
human BAFF and inhibits its biological activity (1,16). 
It selectively reduces the numbers of cluster of differen-
tiation 20-positive (CD20+) B lymphocyte subsets, short-
lived plasma cells, and anti-dsDNA antibody titers in 
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patients with SLE (42). A phase 3, randomized controlled 
trial (RCT) looking at 867 patients from 90 centers in 13 
countries suggested that BAFF blockade, like belimumab, 
has the potential to be the first targeted biological treatment 
approved specifically for the treatment of SLE (29).
Bone marrow-derived mesenchymal stem cells (BM- 
MSCs) are multipotent stem cells capable of differentiating 
into a variety of cell types including osteoblasts, chon-
drocytes, adipocytes, and myoblasts (12,32). In addition, 
MSCs can inhibit immune responses both in vitro and in 
vivo in a dose-dependent, non-human leukocyte antigen 
(HLA)-restricted manner (8,9,17,18,20). These unique 
properties make MSCs attractive candidates for cell ther-
apy for autoimmune disorders such as SLE. Up to now, 
our research center is the first unit engaged in MSCT 
for treatment of SLE. Our clinical trials have showed 
that patients improved with a marked decrease in the 
Systemic Lupus Erythematosus Disease Activity Index 
(SLEDAI) scores and anti-double-stranded DNA levels, 
although the mechanism is not so clear (21,22,38–40,48). 
A previous report described MSC-mediated inhibition of 
human peripheral B-cell proliferation and differentiation 
into immunoglobulin-secreting cells (8), which suggests 
that B-cell might be a target of MSCs in the treatment 
of SLE.
In the present study, we sought to investigate the 
effect of BM-MSC transplantation on B-cell activation 
and BAFF expression and assessed the role of these 
effects in the amelioration of SLE in Murphy Roths 
Large-lymphoproliferation spontaneous mutation (MRL/
lpr) mice.
MATERIALS AND METHODS
Mice
Female MRL/Mp-lpr/lpr (MRL/lpr) mice and female 
Balb/c mice were purchased from Shanghai Laboratory 
Animal Center (Shanghai, China) and bred in our institu-
tion. The animal experiments were approved by the Ethics 
Committee for Animal Research of the Affiliated Drum 
Tower Hospital of Nanjing University Medical School. 
Female MRL/lpr mice were divided into three groups and 
treated with either intravenous injection of BM-MSCs 
derived from Balb/c (MSCT; n = 9), BM nonadherent cells 
(treatment control; n = 9), or saline (placebo; n = 11) at 18 
weeks of age. All cells were given at doses of 1 × 106 per 
mouse. The Balb/c mice (n = 9) were used as a control group 
and received no treatment. Mice were tested for proteinu-
ria every 2 weeks with Coomassie Brilliant Blue (Tianjing 
Boyi Chemical Reagent, Co. Ltd., Tianjin, China). All mice 
were sacrificed at the age of 26 weeks (Fig. 1A).
Cell Culture
MSCs were obtained from Balb/c mice (female, 
4–6 weeks of age). Bone marrow cells were harvested 
from femurs and tibias using the methods described 
by Dobson et al. (10) and were then cultivated in a plastic 
dish (Corning, Inc., Corning, NY, USA) according 
to the protocol for isolation and expansion of MSCs 
developed by Peister et al. (31). MSCs were then 
prepared for transplantation at a concentration of 
2 × 106 cells/ml.
B-Cell Isolation and Culture
Mononuclear cells (MNCs) were isolated from the 
spleens of mice. Cell suspensions were treated with mouse 
B-cell-negative isolation kit, according to the instructions 
of the manufacturer (Miltenyi Biotec, Inc., Auburn, CA, 
USA). Negatively selected cells contained, on average, 
96% B-cells, as assessed by flow cytometric analysis with 
a B220 monoclonal antibody. All cell cultures were per-
formed in Roswell Park Memorial Institute (RPMI) 1640 
medium (Gibco, Gaithersburg, MD, USA) supplemented 
with 10% fetal bovine serum (FBS; Gibco), 100 U/ml 
penicillin, and 100 μg/ml streptomycin (both Hyclone, 
Logan, UT, USA), in the absence or presence of the fol-
lowing stimuli: the cytosine-phosphate-guanine (CpG) 
synthetic oligonucleotide (2.5 μg/ml; R&D Systems, 
Minneapolis, MN, USA), recombinant cluster of dif-
ferentiation 40 ligand (rCD40L, 100 ng/ml; PeproTech, 
Rocky Hill, NJ, USA), goat anti-mouse IgG (2 μg/ml; 
Southern Biotech, Birmingham, AL, USA), interleukin-2 
(IL-2, 50 U/ml; PeproTech), IL-4 (10 ng/ml; PeproTech), 
and IL-10 (10 ng/ml; PeproTech).
Dendritic Cell Isolation and Culture
Dendritic cells (DCs) were generated from bone 
marrow progenitor cells as previously described with 
some modifications (26). Briefly, bone marrow cells 
were isolated from tibiae and femurs of mice and were 
treated with red blood cell lysing buffer [150 mM NH4Cl 
(Beijing Chemical Reagent, Co. Ltd., Beijing, China), 
10 mM NaHCO3 (Shanghai Lingfeng Chemical Reagent, 
Co. Ltd., Shanghai, China), and 0.4% EDTA (Nanjing 
Sunshine Biotechnology, Co. Ltd., Nanjing, China)]. 
Cell density was adjusted to 1 × 106 cells with complete 
medium [RPMI 1640 supplemented with 10% FBS, 100 
U/ml penicillin, 100 g/ml streptomycin, 10 ng/ml recom-
binant granulocyte macrophage colony-stimulating factor 
(GM-CSF; R&D Systems), and 1 ng/ml recombinant IL-4 
(R&D Systems)] and seeded into 12-well plates (Corning) 
at 2 ml/well. All cultures were incubated at 37°C in 5% 
humidified CO2. Nonadherent granulocytes were removed 
after 48 h of culture and then fresh complete medium 
was added. Media were exchanged by half every 48 h. 
After 6 days of culture, nonadherent and loosely adher-
ent cells were harvested, and >85% of the cells expressed 
characteristic DC-specific markers as determined by 
 fluorescence-activated cell sorting (FACS).
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Flow Cytometry
The antibodies (Abs) used for flow cytometry were 
allophycocyanine (APC)-, fluorescein isothiocyanate 
(FITC)-, phycoerythrin (PE)-, or phycoerythrin-cyanine 
5.5 (PE-Cy5.5)-conjugated anti-mouse B220, CD138, 
CD69, CD21, CD23, IgD, and IgM. All Abs described 
were purchased from eBioscience (San Diego, CA, 
USA) except for IgD, which was purchased from BD 
Pharmingen (San Diego, CA, USA). The cultured cells 
were collected, washed twice, and resuspended in 200 μl of 
phosphate-buffered saline (PBS; Wuhan Boster Biological 
Technology, Co. Ltd., Wuhan, China) containing 0.1% 
bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, 
MO, USA). These cells were stained with specific labeled 
Abs or appropriate isotypic controls. The cells were incu-
bated on ice for 30 min, washed with PBS containing 0.1% 
BSA, and then fixed with a 1% paraformaldehyde (Xilong 
Chemical Reagent, Co. Ltd., Shantou, Guangdong, China) 
solution. Analyses were performed using FACScan and 
CellQuest software (BD Bioscience, San Jose, CA, USA).
ELISA
Quantitation of Serum Levels of Anti-dsDNA, BAFF, 
Interferon (IFN)-g, IL-10, and Transforming Growth 
Factor (TGF)-b. Serum from treated and untreated mice 
was harvested and immediately frozen at −80°C until 
Figure 1. Reduction of the 24-h proteinuria and serum anti-dsDNA antibody level of MRL/lpr mice. (A) Schema of bone mar-
row mesenchymal stem cell transplantation (MSCT) procedure. Bone marrow-derived mesenchymal stem cells (BM-MSCs; n = 9), 
1 × 106, BM nonadherent cells (treatment control) (n = 9), or saline (placebo) (n = 11) were infused into female Murphy Roths Large-
lymphoproliferation spontaneous mutation (MRL/lpr) mice through the tail vein. The Balb/c mice (n = 9) were used as a control group 
and received no treatment. Mice were tested for proteinuria every 2 weeks by Coomassie Brilliant Blue. All groups were sacrificed 
at 26 weeks for sample collection. (B) The 24-h proteinuria of mice in the placebo group increased gradually over the 18-week time 
frame. At 26 weeks, the 24-h proteinuria in the MSCT group (2.71 ± 0.78 mg) was significantly decreased compared to the placebo 
group (5.21 ± 1.18 mg) (p < 0.01). (C) There was significant difference in anti-double-strand DNA (dsDNA) titers between the treat-
ment and control groups at the age of 26 weeks. (D) MSCT reduced basal membrane disorder and mesangium cell overgrowth in glom-
erular (upper panels, H&E staining, scale bar: 50 μm; upper second panels, PAS staining, scale bar: 50 μm). Immunohistochemistry 
showed that MSCT was able to diminish IgM and IgG deposition in glomerular of MRL/lpr mice (lower panels, scale bars: 20 μm). 
Electron-dense deposits in both mesangial and subepithelial areas were readily seen in kidneys of control groups (bottom, scale bars: 
100 μm). Results are representative of three independent experiments. A probability of null hypothesis <5% was considered statisti-
cally significant. *p < 0.05; **p < 0.01.
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its use. The concentration levels of anti-dsDNA, BAFF, 
IFN-g, IL-10, and TGF-b were measured by commercial 
kits according to the recommendations of the manufac-
turer (R&D Systems, Minneapolis, MN, USA).
Quantitation of the Levels of IgM, IgG, and IgA. We 
collected the supernatant from cell culture and immedi-
ately froze it at −80°C until its use. The concentration 
levels of IgM, IgG, and IgA were measured by commer-
cial kits according to the recommendations of the manu-
facturer (R&D Systems).
Histological Analysis of Mouse Kidneys and Spleens
The kidneys and spleens were fixed in 10% for-
malin (Xilong Chemical Reagent, Co. Ltd.) for 24 h at 
4°C. Serial 5-μm-thick kidney and spleen sections were 
mounted on glass slides coated with 10% poly-l-lysine 
(Nanjing Chemical Reagent, Co. Ltd., Nanjing, China). 
Paraffin sections (4 μm) were stained with periodic acid–
Schiff (PAS; Nanjing Chemical Reagent, Co. Ltd.) and 
hematoxylin and eosin (H&E; Nanjing Chemical Reagent, 
Co. Ltd.) reagents. Two kidneys of each group were pre-
pared for transmission electron microscopy. The kidney 
was prefixed in 4% glutaraldehyde (Shanghai Lingfeng 
Chemical Reagent, Co. Ltd.) at 4°C for 60 min and 
then it was washed with 0.1% sodium cacodylate buffer 
(pH 7.2–7.4; Nanjing Chemical Reagent, Co. Ltd.) four 
times for 15 min at 4°C, stained with 1% osmic acid 
(Shanghai Shenbo Chemical Co. Ltd., Shanghai, China) 
for 2 h, and poached in double distilled water for 10 min. 
The samples, attached to grids, were dehydrated in ethanol 
and were dried. Ultrathin sections were cut using an ultra-
microtome (Zhejiang Boyi Medical Equipment Factory, 
Zhejiang, China) and stained with both uranyl acetate 
(Nanjing Chemical Reagent, Co. Ltd.) and lead citrate 
(Shanghai No. 1 Chemical Reagent, Co. Ltd., Shanghai, 
China). Sections were observed under a JEM-1230 trans-
mission electron microscope (Hitachi Ltd., Tokyo, Japan) 
at an accelerating voltage of 80 kV by two pathologists 
who were blinded to the treatments.
Immunochemistry. Serial 5-μm-thick kidney and spleen 
sections were mounted on glass slides coated with 10% 
poly-l-lysine. Sections were dewaxed in xylene and rehy-
drated in graded ethanols. Endogenous peroxidase activity 
was blocked by immersion in 0.3% methanolic perox-
ide (Shanghai Lingfeng Chemical Reagent, Co. Ltd.) for 
30 min. Immunoreactivity was enhanced by microwave 
incubating the tissue sections for 10 min in 0.1 M citrate 
buffer (Shanghai No. 1 Chemical Reagent, Co. Ltd.). 
Immunostaining was performed using the avidin-biotin-
peroxidase complex method with the antibodies for BAFF 
(1:200, Abcam, Cambridge, MA, USA), BCMA (1:200, 
Santa Cruz Biotechnologies, Dallas, TX, USA), TACI 
(1:200, Abcam), and BAFF-R (1:200, Abcam). Three 
independent pathologists evaluated the immunostaining. 
At least 10 high-power fields were randomly chosen, and 
at least 300 cells were counted. Images were captured 
using a digital CCD camera system connected to a Zeiss 
microscope (Zeiss, Thornwood, NY, USA).
Immunofluorescence. To detect immune complex 
deposits, cryostat sections (4 μm) were fixed in chilled 
acetone (Nanjing Chemical Reagent, Co. Ltd.) and stained 
with an FITC-conjugated polyclonal goat anti-mouse IgG 
or IgM antibody (Organon Teknica, Scarborough, CA, 
USA). To detect the location of B-cells in the kidneys, 
cryostat sections (4 μm) were fixed in chilled acetone and 
stained with an FITC-conjugated polyclonal goat anti-
mouse B220 or CD138 antibody (eBioscience).
Western Blotting
The kidneys and spleens were lysed with lysis buffer 
(Invitrogen, Carlsbad, CA, USA). Equal amounts of pro-
tein were resolved by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE; Nanjing Biosharp 
Technology, Co. Ltd., Nanjing, China) and transferred 
onto polyvinylidene difluoride (PVDF) membrane filters 
(Millipore Corporation, Billercia, MA, USA). The mem-
branes were first blocked and then incubated with the 
primary antibodies (BAFF, 1:200; BCMA, 1:200; TACI, 
1:200; BAFF-R, 1:200) described above, for 2 h at room 
temperature. Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH; 1:200; Cell Signaling Technology, Danvers, MA, 
USA) was used as a loading control. After three washes, 
filters were incubated with horseradish peroxidase-conju-
gated secondary antibodies (1:200, Santa Cruz) for 1 h at 
room temperature. Detection of immunocomplexes was 
performed with an enhanced chemiluminescence system 
(NEN Life Science Products, Boston, MA, USA).
Statistical Analysis
Quantitative data were expressed as the mean ± SD. 
GraphPad Prism 4 software (Version 4.03; San Diego, 
CA, USA) was used for statistical analysis. Comparisons 
were performed using paired Student’s t test and 
Bonferroni correction. Values of p < 0.05 are considered 
to be significant.
RESULTS
Treatment With MSCs Prolonged Survival and 
Ameliorated Lupus Nephritis in MRL/lpr Mice
Seven mice died in the treatment control group and 
two in the placebo group. On the other hand, all the mice 
in the MSCT group survived until sacrifice. Owing to 
the death of seven of the nine treatment control mice, 
this group is not reported here and reference to the con-
trols refers to the untreated Balb/c mice. MSCT also sig-
nificantly reduced 24-h proteinuria (Fig. 1B) and serum 
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levels of anti-dsDNA antibody (Fig. 1C). At 26 weeks, 
the 24-h proteinuria in the MSCT group was signifi-
cantly lower (2.71 ± 1.78 mg) than in the placebo group 
(5.21 ± 2.18 mg) (p < 0.05). The serum level of anti-
dsDNA was significantly reduced in the MSCT mice 
(3,415 ± 681 IU/ml) compared with that in the placebo 
(5,752 ± 1,425 IU/ml) (p < 0.01).
Histological examination of kidneys of placebo mice 
at 26 weeks showed typical glomerulonephritis, charac-
terized by enlarged glomeruli, proliferation of glomerular 
cells, infiltrating inflammatory cells, increased mesangial 
matrix, and crescent formation (Fig. 1D). In contrast, 
MSCT-treated mice showed a marked reduction of glom-
erulonephritis, varying degrees of focal glomerular cell 
proliferation, occasional inflammatory cells, and only a 
slight increase in mesangial matrix.
Immunofluorescence staining of the kidneys in the pla-
cebo group showed IgM and IgG deposited extensively 
under the mesangium, in the subepithelium and suben-
dothelium. In the MSCT group, IgM and IgG deposition 
significantly decreased. The presence of immune com-
plexes was further confirmed by electron microscopic 
analysis. Electron-dense deposits in both mesangial and 
subepithelial areas were readily seen in kidneys of con-
trol groups.
Treatment With MSCs Downregulates the Maturation 
and Differentiation of B-Cells of MRL/lpr Mice
Since we found reduced antibody production after 
MSCT, we further looked for changes in the population 
of mature B-cells in the spleens of placebo or MSCT-
treated lupus mice. As shown in Figure 2, treatment with 
MSCT resulted in a significant reduction in the number 
of spleen cells (Fig. 2A) and in the B220+ (Fig. 2B) cell 
counts. Figure 2C and D demonstrates the percentage and 
absolute numbers of mature (IgM+IgD+) B-cells out of the 
total B-cell population. Figure 2E shows representative 
dot plots of the latter. The percentage of IgM+IgD+ B-cells 
was significantly reduced in MSCT-treated mice, as was 
the number of IgM+IgD+ cells. The percentage and abso-
lute numbers of plasma cells seems to be decreased in 
the MSCT group, but there was no statistical significance 
(data not shown).
We further tested the effect of treatment with BM- 
MSCs on the B-cell intermediate differentiation stages 
defined as T1 (B220+CD23−CD21−IgMhigh) and T2 (B220+ 
CD23+CD21highIgMhigh). Figure 2F–J presents the percent-
ages and absolute numbers of B-cells at the T1 and T2 
stages in the different experimental groups. The percent-
ages of T1 cells out of the a total of B220 cells diminished 
significantly (7.26 ± 4.02% T1 and 4.84 ± 2.67% T2 in the 
placebo groups vs. 3.43 ± 2.07% T1 and 2.56 ± 1.39% 
T2 in MSCT mice), following transplantation of BM- 
MSCs (Fig. 2F and H). Similar results are shown for the 
total numbers of T1 and T2 cells (5.09 ± 2.00 × 106 T1 
and 3.68 ± 1.73 × 106 T2 in the placebo groups versus 2.71 ± 
1.71 × 106 T1 and 1.95 ± 1.19 × 106 T2 in MSCT mice) 
(Fig. 2G and I). Figure 2J shows representative dot plots 
of the latter. Thus, MSCT downregulates the maturation 
and differentiation of B-cells in MRL/lpr mice, which are 
generally elevated in lupus.
BM-MSCs Inhibit B-Cell Activation and 
Immunoglobulin Production In Vitro
We next investigated the effects of BM-MSCs on 
B-cell activation and stimulation with CpG, rCD40L, anti-
immunoglobulin antibodies, IL-2, and IL-4. Inhibition 
of B-cell activation by the percentage of B220+CD69+ 
cells was observed at the B-cell/BM-MSC ratio of 1:1 
(p < 0.03) (Fig. 3A). This effect was also detectable by 
supernatant from BM-MSCs cultured with B-cells.
Purified B-cells were next incubated with or without 
BM-MSCs at 1:1 and 1:5 ratios in the presence of CpG, 
CD40L, anti-immunoglobulin, IL-2, IL-4, and IL-10. 
BM-MSCs inhibited the production of IgM, IgG, and IgA 
at a B-cell/MSC ratio of 1:1 (p < 0.01 for IgM, p < 0.05 for 
IgG, p < 0.05 for IgA), as assessed by ELISA (Fig. 3B). No 
inhibition of immunoglobulin production was observed 
at 1:5 B-cell/MSC ratio (data not shown).
Treatment With MSCs Downregulates the Expression of 
Serum BAFF in MRL/lpr Mice, While BM-MSCs Reduce 
the Production of BAFF by Suppressing DCs In Vitro
Since the expression of BAFF was reported to be ele-
vated in patients with SLE and in lupus mouse models 
(38,44), it was of interest to determine the effect of treat-
ment with MSCT on BAFF secretion. As shown in Figure 
4A, MSCT significantly inhibited the secretion of BAFF 
(control −4.23 ± 1.82 ng/ml, placebo −46.99 ± 12.57 ng/ml, 
MSCT −24.78 ± 18.71 ng/ml). Since IFN-g and IL-10 are 
pathogenic cytokines in SLE and are reported to activate 
BAFF (5), we tested whether the reduction in BAFF was 
associated with a diminished secretion of those cytokines. 
As shown in Figure 4B and C, MSCT significantly inhib-
ited the secretion of IL-10 (control −4.06 ± 3.58 pg/ml, 
placebo −46.07 ± 17.63 pg/ml, MSCT −18.94 ± 7.05 pg/ml). 
The levels of IFN-g were also downregulated, but with 
no statistical significance. Meanwhile, the immunosup-
pressive cytokine TGF-b in serum was upregulated by 
MSCT (Fig. 4D) (control −11.14 ± 5.57 ng/ml, placebo 
−2.43 ± 0.92 ng/ml, MSCT −3.58 ± 1.22 ng/ml). Thus, 
the downregulated production of BAFF following trans-
plantation of BM-MSCs might be, at least partially, due 
to the diminished secretion of IL-10 and increased secre-
tion of TGF-b.
Since BAFF is mainly expressed by T-cells and dendritic 
cells, we next incubated BM-MSCs and DCs together. 
Purified DCs were stimulated with CpG for 24 h (DC¢), 
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were next incubated with BM-MSCs at 1:1 and 1:10 ratios 
or incubated with BM-MSCs for 3 days, and were next 
stimulated with CpG for 24 h. Inhibition of BAFF produc-
tion was observed at all the conditions tested (Fig. 4E).
MSCs Inhibit BAFF Secretion Levels and Its Receptors 
in the Spleens and Kidneys of MRL/lpr Mice
Next, we examined the levels of BAFF and its recep-
tors in kidneys and spleens of mice treated with placebo 
or MSCs. Immunohistochemical examination of kidney 
sections revealed that positive staining of BAFF and its 
receptors was mainly located in the glomerular mesan-
gium, renal interstitium, and the renal tubule inflammatory 
cell infiltrate. Positive staining in the renal tubule was 
located on the edges and lumens of the tubules in the 
placebo group (Fig. 5A). In the MSCT group, expres-
sion of BAFF and its receptor was much lower than in 
the placebo group (Fig. 5A, B). Immunoblotting analy-
sis showed similar expression patterns of BAFF and its 
receptors in kidneys and spleens (Fig. 5C).
DISCUSSION
SLE is a systemic autoimmune disease characterized 
by continuous generation of autoantibody-producing cells. 
It is well established that B-cells are critical in the patho-
genesis of the disease through autoantibody- dependent 
Figure 3. BM-MSCs inhibit B-cell activation and immunoglobulin production in vitro. (A) B-cells purified from the spleens of MRL/
lpr mice were cocultured for 3 days with allogeneic BM-MSC suspensions at 1:1 ratios or supernatant from BM-MSCs cultured in 
the presence of cytosine-phosphate-guanine (CpG), recombinant cluster of differentiation 40 ligand (rCD40L), anti-IgG antibodies, 
interleukin (IL)-2, and IL-4. Maximum and minimum values of B-cells (B220+CD69+) from five independent experiments are shown. 
*p < 0.05. (B) Purified B-cells were incubated for 7 days with or without BM-MSCs at a 1:1 ratio in the presence of CpG, rCD40L, 
anti-IgG antibodies, IL-2, IL-4, and IL-10. The secretion of IgM, IgG, IgA was evaluated by ELISA. Maximum and minimum values 
from five independent experiments are shown. *p < 0.05. **p < 0.01.
FACING PAGE
Figure 2. B-cell maturation and differentiation are downregulated in MSCT mice. Spleen cells of mice were harvested following treat-
ment experiments and were stained with antibodies to B220, IgM, IgD, cluster of differentiation 21 (CD21), and CD23. Means of total 
spleen cell counts (A), B220+ cell counts (B), percentage of IgM+IgD+ B-cells out of the total B-cell population (C), absolute numbers 
of IgM+IgD+ B-cells (D), representative dot plots of IgM+IgD+ B-cell staining (E) of five independent experiments. Mean percentages 
(F) and numbers (G) of T1 (B220+CD23−CD21−IgMhigh) B-cells out of the total B-cell population of five experiments. Mean percent-
ages (H) and numbers (I) of T2 (B220+CD23+CD21highIgMhigh) B-cells and (J) representative dot plots of CD21 and CD23 on gated 
B220+IgMhigh cells of five experiments. A probability of null hypothesis <5% was considered statistically significant. *p ≤ 0.05.
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Figure 4. The effect of treatment with MSCT on the expression of B-cell activating factor (BAFF) and interferon (IFN)-g, 
interleukin-10 (IL-10), and transforming growth factor (TGF)-b secretion. (A) Mean secretion of BAFF in serum measured by ELISA. 
(B) Mean secretion of interferon IFN-g in serum measured by ELISA. (C) Mean secretion of IL-10 in serum measured by ELISA. 
(D) Mean secretion of TGF-b in serum measured by ELISA. (E) The inhibition of BAFF production at the BM-MSCs/dendritic cells 
(DCs) ratio of 1:1 and 1:10. DCs´: Purified DCs stimulated with CpG for 24 h before BM-MSC exposure. Results are representative of 
three independent experiments. A probability of null hypothesis <5% was considered statistically significant. *p < 0.05. **p < 0.01.
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Figure 5. The expression of BAFF, BAFF-R, BCMA, and TACI in spleens and kidneys. (A) Expression of BAFF and its receptors 
[BAFF-R, B-cell maturation antigen (BCMA) and transmembrane activator and calcium modulator ligand interactor (TACI)] in the 
kidneys of MRL/lpr mice treated with placebo or MSCT were detected by immunohistochemistry (scale bars: 20 μm). (B) Expression 
of BAFF and its receptors in the spleens of MRL/lpr mice treated with placebo or MSCT were detected by immunohistochemistry 
(scale bars: 20 μm). (C) Western blots of BAFF and its receptor expression in kidneys and spleens (representative of three experi-
ments performed). A probability of null hypothesis <5% was considered statistically significant. GAPDH: glyceraldehyde 3-phosphate 
dehydrogenase. *p < 0.05.
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and -independent mechanisms. We have shown that the 
transplantation of allogeneic BM-MSCs could inhibit 
the maturation and differentiation of B-cells of MRL/lpr 
mice, especially the mature (IgM+IgD+) and transitional 
(T1 and T2) B-cell populations. BM-MSCs also inhibited 
the activation and immunoglobulin production in vitro.
BAFF overproduction was reported to be associated 
with autoimmune and lymphoproliferative disorders such 
as SLE (7,45), rheumatoid arthritis (7), Sjogren’s syn-
drome (14), and multiple myeloma (30). In SLE patients, 
as in lupus-prone mouse models, BAFF serum levels 
and gene expression were reported to be significantly 
higher than in healthy controls (7,15,34,47). In normal 
mice, the exogenous addition of BAFF enhanced the anti-
body responses to antigen challenge, whereas treatments 
that blocked BAFF inhibited those responses (2,35,41). 
In the present study, we found that transplantation of 
BM-MSCs, which ameliorated serological and clinical 
manifestations of SLE in spontaneous and induced mouse 
models (38,40,48), significantly reduced the serum levels 
and expression of BAFF in kidneys and spleens (Figs. 4 
and 5). The effect of MSCT was specific since the injec-
tion of saline did not significantly affect the expression 
and secretion of BAFF. In agreement, the blocking of 
BAFF in animal models of autoimmune diseases (arthri-
tis, spontaneous B lymphocyte autoimmunity, and SLE) 
reduced autoantibody production and disease manifesta-
tions (19,24,43).
Reports on the effects of BAFF in Tg mice indicate that 
BAFF induces T1, T2, and marginal zone (MZ) B-cells 
in the periphery and that, in BAFF-deficient mice, the 
maturation of B-cells is inhibited (28). Moreover, BAFF 
was reported to regulate B-cell survival (11). In our study, 
we observed a significant and specific reduction in the 
mature (IgM+IgD+) and transitional (T1 and T2) B-cell 
populations in spleens of MSCT mice (Fig. 2). It is likely 
that the reduced BAFF levels following transplantation of 
BM-MSCs led to the decrease in transitional and mature 
B-cell populations. The reduction in T1 B-cells, which 
were shown to be not affected by BAFF (35), is probably 
due to the additional effects of MSCT that are distinct 
from BAFF blockade.
Both IFN-g and IL-10, two pathogenic cytokines in 
SLE, were reported to stimulate BAFF expression by 
activating macrophages, monocytes, and dendritic cells 
(26). On the other hand, TGF-b, an immunosuppressive 
cytokine, is downregulated in lupus (37). In this study, we 
detected a significant and specific reduction in IL-10 secretion 
in MSCT mice. The secretion of IFN-g was also decreased 
in MSCT mice. The secretion of TGF-b was upregulated in 
the MSCT groups compared with the placebo or treatment 
control. Thus, it is possible that the downregulated IL-10 
and upregulated TGF-b played a role in diminishing the 
levels of BAFF. Since dendritic cells are considered the 
main producers of BAFF (2), we incubated BM-MSCs and 
DCs together to see whether MSCs could inhibit the pro-
duction of BAFF. We found that the production of BAFF 
by DCs can be suppressed by MSCs. Therefore, we think 
that the MSCs may modulate B-cell populations through 
its effects on BAFF. This may be one of the ways that the 
MSCs indirectly inhibit B-cell function.
In this study, we showed that BM-MSCs inhibit in vitro 
B-cell activation and immunoglobulin production. B-cells 
isolated from the spleen of mice were stimulated with CpG, 
rCD40L, anti-immunoglobulin antibodies, IL-2, and IL-4. 
Such a cocktail provides an optimal trigger for most B-cell 
effector functions (3), thus, allowing investigation of the 
direct effects of BM-MSCs on B-cell activities. Following 
culture with BM-MSCs, B-cell activation and immuno-
globulin production were significantly impaired. In our 
previous studies, we found that the effects of umbilical 
cord MSCs on B-cells appeared to be strongly influenced 
by the relative in vitro concentrations, as suggested by a 
gradual loss of inhibition observed at lower MSC/B-cell 
ratios. MSCs markedly suppressed B-cell differentiation 
as shown by the decreased number of CD138+ cells and 
reduced levels of IgM and IgG production in coculture. 
As revealed by transwell experiments, soluble factors pro-
duced by MSCs might be involved in mediating B-cell 
suppression. The maximum inhibition effect was observed 
at the MSC/B-cell ratio of 1:1. This inhibitory effect was 
still detectable at a 1:10 ratio of MSC/B-cell and dimin-
ished at 1:100 ratios (6). T-cell activation is strongly inhib-
ited by MSCs even at low concentrations of MSCs (46), so 
we cannot exclude that their in vivo effect on B-cells may 
be stronger when T-cell help is required. Although we and 
others have observed that MSCs could induce T-cell apop-
tosis, in the present study, we did not observe significant 
B-cell apoptosis. We noted that previous studies showed 
that B-cell proliferation was inhibited by MSCs through an 
arrest in the G0/G1 phase of the cell cycle and not through 
the induction of apoptosis (8). Another study found that 
MSC and its supernatant inhibit B lymphocyte prolifera-
tion with the mechanism correlated with the MSC concen-
tration and the MSC-secreted cytokines, but MSCs do not 
induce B lymphocyte apoptosis in vitro (44).
In conclusion, the findings of this study provide a new 
basis for the rationalization of the therapeutic effect of 
BM-MSC transplantation. Indeed, this study demonstrated 
that the mechanisms of action by which MSCT suppresses 
hyperreactive B-cells involve BAFF at multiple levels. 
Transplantation of BM-MSCs downregulates the expres-
sion and secretion of IFN-g and IL-10 and upregulates the 
levels of TGF-b, leading to reduced levels of serum and 
peripheral BAFF expression. Reduction of BAFF down-
regulates T1, T2, and mature B-cell populations and then 
plays a role in disease progression. Reduction of matura-
tion and differentiation of B-cells results in diminishing 
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levels of serum autoantibodies and 24-h proteinuria, 
reducing renal damage. In short, in addition to the promi-
nent inhibitory effects on T-cells, MSCT may modulate 
B-cell populations through its effects on BAFF.
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